The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Novo Nordisk resumed its rally on Tuesday, rising to the top of the Stoxx 600 and adding 5.7% by the closing bell. Shares of ...

Alvotech (ALVO), a commercial-stage global biotech company specializing in the development and manufacture of biosimilar medicines, ...

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...

AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...

Ladenburg raised the firm’s price target on Biodexa Pharmaceuticals (BDRX) to $18 from $8 and keeps a Buy rating on the shares. The company ...

Pomalidomide is under clinical development by Qilu Pharmaceutical and currently in Phase III for Refractory Multiple Myeloma.

NEFECON (R) was included in the NRDL in November 2024. As the first IgAN etiological treatment drug fully approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA ...

While investigations have unearthed a dirty nexus between those indulging in supplying spurious drugs without Active ...

Everest Medicines announces the implementation of Nefecon NRDL pricing in China for the treatment for IgA nephropathy: Shanghai, China Saturday, January 4, 2025, 10:00 Hrs [IST] E ...